Pipeline DevelopmentThe pipeline includes four additional programs with differentiated mechanisms of action, offering diversified exposure to a multibillion-dollar market with no approved therapies.

Bears Say

Program DiscontinuationThe discontinuation of VS-01 in ACLF followed a serious adverse event of peritonitis, making VS-01 unsuitable for ACLF patients.

Short-Term ChallengesThe discontinuation of VS-01 in ACLF is a near term headwind due to the fragile ICU patient population and elevated infection risk.

Genfit SA News

Genfit Advances Liver Pipeline With Completed Phase 1 G1090N Study

Genfit ($GNFTY) announced an update on their ongoing clinical study. Study Overview Genfit is running a Phase 1...

7d ago

GNFTY

GNFTY FAQ

What was Genfit SA’s price range in the past 12 months?

Genfit SA lowest stock price was $2.55 and its highest was $6.51 in the past 12 months.

What is Genfit SA’s market cap?

Genfit SA’s market cap is $305.92M.

When is Genfit SA’s upcoming earnings report date?

Genfit SA’s upcoming earnings report date is Apr 02, 2026 which is in 69 days.

How were Genfit SA’s earnings last quarter?

Genfit SA released its earnings results on Sep 22, 2025. The company reported -$0.236 earnings per share for the quarter, missing the consensus estimate of $1.192 by -$1.428.

Is Genfit SA overvalued?

According to Wall Street analysts Genfit SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Genfit SA pay dividends?

Genfit SA does not currently pay dividends.

What is Genfit SA’s EPS estimate?

Genfit SA’s EPS estimate is 0.02.

How many shares outstanding does Genfit SA have?

Genfit SA has 50,036,790 shares outstanding.

What happened to Genfit SA’s price movement after its last earnings report?

Genfit SA reported an EPS of -$0.236 in its last earnings report, missing expectations of $1.192. Following the earnings report the stock price went down -12.53%.

Which hedge fund is a major shareholder of Genfit SA?

Currently, no hedge funds are holding shares in GNFTY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Genfit SA Stock Smart Score

Neutral

Technicals

Fundamentals

Return on Equity

-51.06%

Trailing 12-Months

Asset Growth

22.06%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Genfit SA

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.